PDUFA VI: NORD Wants Reviewers To Be More Accessible
As rare disease experts become part of orphan drug reviews, stakeholder group says they also should be more accessible to the public.
As rare disease experts become part of orphan drug reviews, stakeholder group says they also should be more accessible to the public.